Metrasens Spotlights New Excellence in MRI Safety Program™ for MRI Safety Week

July 22, 2013

Metrasens, the world leading provider of ferromagnetic detection systems (FMDs) for safety in Magnetic Resonance Imaging (MRI) facilities is proud to support MRI Safety Week 2013. The company will be spotlighting its new Excellence in MRI Safety Program™ at The Association for Medical Imaging Management’s (AHRA) 41st Annual Meeting in Minneapolis.

Lisle, IL (PRWEB) July 22, 2013

During MRI Safety Week, this year running from July 22-28, MRI professionals around the world emphasize the vital importance of safety in their work environments. Metrasens’ Excellence in MRI Safety program is a new and comprehensive approach that empowers facilities to provide safer environments for patients and staff alike.

The program takes current best practice as recommended by ACR, ASHE and Joint Commission ensuring everyone, from Medical Leadership to front-line Technologists, fully understand the inherent risks in the MRI environment and how they may be effectively mitigated. Building on the power of Metrasens’ Ferroguard FMDs solutions, the program assists facilities in their creation of a culture of safety by means of self-assessment, development of robust procedures, and ensuring high levels of staff competence. See http://www.ferroguard.com.

About Metrasens:

Metrasens is the provider of the Ferroguard range of ferromagnetic detection systems for protecting MRI facilities from the dangers of projectile accidents. The world-leading sensor technology in Ferroguard provides the highest sensitivity FMD available, resulting in the greatest detection reliability and confidence. It has a growing network of international distribution partners including Philips, Invivo, Siemens, GE, and ETS-Lindgren. Metrasens’ advanced magnetic-detection core technologies are also being successfully employed in the rapidly growing worldwide security markets. Complete information is available at the company’s website: http://www.metrasens.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10950646.htm

Source: prweb

comments powered by Disqus